EGFR and breast carcinoma: Although automated analysis of TMAs has proven to be effective for specific screening protocols, particularly in breast cancer (Turbin et al, 2008; Bolton et al, 2010; Konsti et al, 2011; Howat et al, 2015), it was also observed that algorithms underperform on less well-established markers such as cytokeratin (CK) 5/6 and epidermal growth factor receptor 1 (EGFR/HER1; Howat et al, 2015).